Control of Inflammation in Pancreatic β-cells: Role of Arylpyrazole Compounds
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Abstract

Figure 2. Schematic Representation of Arylpyrazole-mediated activation of anti-inflammatory proteins, depicting both genomic
and non-genomic mechanisms of action. Genomic Mechanism. The arylpyrazole compound passes through the phospholipid bilayer
membrane into the cytosol where it forms a dimer with the glucocorticoid (GC) receptor. This dimer passes into the nucleus where it
binds to the glucocorticoid response element (GRE). This activates transcription of mRNA for the biosynthesis of anti-inflammatory
proteins. Non-genomic Mechanism. The arylpyrazole-GC receptor dimer can directly inhibit the activity of the inflammatory proteins
within the cytosol.
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•Arylpyrazole 4 inhibits IL-1β-mediated CCL2 transcription by >50% in the 832/13 cell line.
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•Arylpyrazole 4 activated transcription from a synthetic GRE containing a luciferase promoter.
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Figure 4. Chemical Structures of Dexamethasone, Arylpyrazole 4, and Arylpyrazole 5 contribute to different downstream antiinflammatory activity. A. Dexamethasone, a synthetic glucocorticoid, possesses many reactive alcohol functional groups,
contributing to its ability to suppress IL-1β signaling and activation of the GRE. B. Arylpyrazole 4 possesses a reactive alcohol group,
which mediates its affinity as a ligand for intracellular glucocorticoid receptors. C. The ketone functional group in Arylpyrazole 5
contributed to its inability to significantly suppress IL-1β signaling.
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Type 1 Diabetes Mellitus (T1DM) is an autoimmune disease characterized by the destruction of
the insulin-producing pancreatic islet β-cells leading to elevations in blood glucose levels.
Destruction of islet β-cells results from immune-cell infiltration into the islets and ensuing
production of pro-inflammatory cytokines, such as interleukin-1β (IL-1β), from such cells.
IL-1β signals through receptors on the β-cell surface, which leads to the production of
chemoattractant proteins called chemokines directly from the β-cells. This process produces a
continuous inflammatory response that leads to β-cell death and dysfunction associated with the
development of T1DM. Thus, novel therapeutic interventions that reduce or slow the
progression of the inflammatory response within the pancreatic β-cells would be beneficial for
treatment or cure of T1DM. One approach to reduce inflammation in a variety of human
diseases is the administration of synthetic glucocorticoids. Glucocorticoids act through an
intracellular receptor to elicit anti-inflammatory actions. However, current glucocorticoid
receptor agonists impair β-cell function, which limits their clinical effectiveness. Thus, the
current project investigated whether two non-steroidal arylpyrazole compounds were able to
mimic the anti-inflammatory effects of glucocorticoids by suppressing known inflammatory
responses in pancreatic β-cells. Using luciferase-based reporter assays as a measure of
inflammatory gene activation revealed that Arylpyrazole 4 (AP4) significantly suppressed
maximal IL-1β response starting at 100nM whereas Arylpyrazole 5 (AP5) did not significantly
suppress the IL-1β response. When applied to a 3xGRE promoter, AP4 significantly activated
the GRE at 100nM dosage whereas AP5 showed no activation of the GRE. The difference
between these two compounds was an alcohol functional group present in the AP4 versus the
ketone in AP5. We conclude that the difference in anti-inflammatory activity of AP4 and AP5
are due to distinct structure-function relationships with the ligand (AP) and glucocorticoid
receptor. These preliminary findings will serve as the foundation for future investigation as to
how the arylpyrazole scaffold can be modified to produce anti-inflammatory activities in
pancreatic β-cells without suppressing insulin secretion.
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• Arylpyrazole 5 did not significantly inhibit pro-inflammatory cytokine IL-1β activity compared
to the control.

Dexamethasone

•Arylpyrazole 5 showed no activation of the GRE promoter compared to the control.
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Understanding the specific role of cytokines as a cellular signal in both the innate and
adaptive immune responses would undoubtedly aid in unveiling the components of the
inappropriate immune response in T1DM. Thus, future research endeavors should investigate
how cytokines regulate the interplay of various types of immune cells during the
development of autoimmune diseases. Another area of study involves investigating the
divergent mechanisms by which the intracellular glucocorticoid receptor functions to inhibit
and activate genetic expression as this would aid in the development of novel drugs utilized
to treat individuals with T1DM.
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Figure 1. Schematic Representation of Genomic Sites Targeted by Intracellular Glucocorticoid Receptors.
A. Recruitment of Glucocorticoid receptors to the NK-κB promoter site can inhibit the transcription of pro-inflammatory
agents. B. A synthetic promoter consisting of three back-to-back GRE sites and a luciferase gene downstream. C. A promoter
consisting of two NK-κB sites and a luciferase gene downstream.
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Figure 3. Arylpyrazole 4 inhibits cytokine IL-1β activity and activates GRE while Arylpyrazole 5 neither inhibits cytokine IL-1β
activity nor activates GRE . A. 832/13 cells were transfected with a plasmid containing the CCL2 (Chemokine ligand 2) promoter
upstream of a luciferase gene. Cells were treated with IL-1β in the absence or presence of increasing doses of Dexamethasone (Dex) for
4 hours. The control consisted of cells only treated with IL-1β and was set at 100% maximal IL-1β response. B. 832/13 cells were
transfected with a plasmid containing a 3xGRE (glucocorticoid response element) promoter upstream of a luciferase gene. Cells were
treated with increasing doses of Dex for 4 hours. The control consisted of cells only treated with dimethyl sulfoxide (DSMO). C. 832/13
cells were transfected with a plasmid containing the CCL2 promoter driving expression of a luciferase gene and were treated with IL-1β
plus increasing doses of Arylpyrazole 4 for 4 hours. The control consisted of cells only treated with IL-1β and was set at 100% maximal
IL-1β response. D. 832/13 cells were transfected with a plasmid containing 3x GRE promoter upstream of a the luciferase gene and
treated with increasing doses of Arylpyrazole 4 for 4 hours. The control consisted of cells only treated with DSMO. E. 832/13 cells were
transfected with a plasmid containing the CCL2 promoter upstream of a luciferase gene and treated with IL-1β plus increasing doses of
Arylpyrazole 5 for 4 hours. The control consisted of cells only treated with IL-1β and was set at 100% maximal IL-1β response. F. 832/13
cells were transfected with a plasmid containing a 3xGRE promoter upstream of a luciferase gene and treated with increasing doses of
Arylpyrazole 5 for 4 hours. The control consisted of cells only treated with DSMO.
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